



#### AperTO - Archivio Istituzionale Open Access dell'Università di Torino

#### **Cystic Fibrosis Mucus Model to Design More Efficient Drug Therapies**

This is the author's manuscript
Original Citation:
Availability:
This version is available http://hdl.handle.net/2318/1841487 since 2022-02-17T10:28:27Z
Published version:
DOI:10.1021/acs.molpharmaceut.1c00644
Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

## Cystic fibrosis mucus model to design more efficient drug therapies

3	
4	Cosmin Butnarasu <sup>*a</sup> , Giulia Caron <sup>a</sup> , Daniela Pacheco <sup>b,c</sup> , Paola Petrini <sup>b</sup> , Sonja Visentin <sup>a</sup>
5	
6 7	<sup>a</sup> University of Torino, Department of Molecular Biotechnology and Health Science, Via Quarello15, 10135 Torino, Italy
8	<sup>b</sup> Department of Chemistry, Materials and Chemical Engineering, Giulio Natta-Politecnico di Milano, Italy
9	Bac3Gel Lda, TagusPark – Edificio Inovacao II, Lisbon, Portugal.
10	
11 12	*Corresponding author: <u>cosminstefan.butnarasu@unito.it</u> ,
13	Keywords: mucus, drugs, permeability, PAMPA, HTS
14	
15	Abstract
16	
17	Mucus can represent a strong barrier to tackle for oral or pulmonary administered
18	drugs especially in mucus-related disorders. Still little is known about the molecular
19	properties that mediate the interaction of drugs with mucus. This study uses a
20	pathological cystic fibrosis (CF) mucus model to investigate the impact of mucus over
21	the permeability of 45 commercial drugs. An <i>in vitro</i> mucosal surface was recreated by
22	coupling the mucus model to 96-well permeable supports pre-coated with structured
23	layers of phospholipids (PAMPA). The mucus model behaved as an interactive filter as
24	different molecular structures reacted differently to mucus. We also found that
25	permeability can be enhanced when calcium salts are formed. This was confirmed also
26	through the use of cystic fibrosis sputum as a rough ex vivo model of CF mucus. Since
27	development of drugs is characterized by a high rate of failure, the mucus platform
28	could aid to reduce at an early stage the number of poor performer drug candidates
29	preventing them to uselessly reach preclinical trials.

#### 31 1. Introduction

32

33 The mucosal surfaces of the human body are constantly exposed to environmental 34 threats. To counteract potential noxious agents, all the wet epithelia are covered with a 35 layer of mucus. Mucus is a dynamic semipermeable network with a heterogeneous 36 composition. It consists of  $\sim$ 95% water and the remaining 5% comprising electrolytes, 37 lipids, DNA fragments and proteins. Maintaining the gel-like properties and keeping 38 together such a huge amount of water requires a strong yet flexible skeleton. The tough 39 job is carried out by mucins. Mucins are long polymeric glycoproteins having high 40 molecular weight, consisting of a peptide backbone to which a huge amount of 41 carbohydrate chains are attached. Such an architecture enables the exchange of 42 nutrients, water, gases and hormones whilst being impermeable to most bacteria and 43 pathogens <sup>1,2</sup>.

44 A delicate balance of mucus production must be achieved as weakening of the mucus 45 barrier makes us more vulnerable to environmental threats. On the contrary, an 46 overproduction or dysfunctional clearance of mucus are hallmarks of the pathogenesis 47 of all the mucus-related pathologies, especially pulmonary diseases<sup>3</sup>, such as cystic 48 fibrosis (CF) among others. In these disorders, an overexpression of mucins, 49 accumulation of extracellular DNA as well cellular debris, and the persistent presence 50 of bacteria, confers mucus stasis lending to a vicious cycle of infection and inflammation 51 that can be chronically sustained <sup>4,5</sup>. In CF and bronchiectasis, sputum production is not 52 only a daily reality, but also a crucial marker for physicians during both stable state and 53 exacerbation used to evaluate disease severity and treatment response. Sputum's 54 reliability as an indicator of disease has led it to being proposed as an important clinical 55 prognostic factor in mucus-related diseases. This has been taken a step further by 56 Murray and colleagues, who explored the utility of sputum color in patients with 57 bronchiectasis by developing a quantitative method that predicts bacterial colonization 58 based on the color of sputum <sup>6</sup>.

59 Despite the great advancements in disease management of the last decades, pulmonary 60 failure remains the main cause of morbidity and mortality in patients with CF. The lack 61 of function of the cystic fibrosis transmembrane conductance regulator protein (CFTR) 62 in people with CF, leads to mucus dehydration. As a result, mucus undergoes a reduced 63 clearance, clogging the airways and making it difficult to breath. Physicians have 64 developed advanced clearance techniques (ACTs) based on coughing maneuvers to get 65 rid of the viscous mucus. In addition to the routinely ACTs, CF patients manage their 66 disease by following a regular treatment with medications. The recurrent pulmonary

exacerbations are usually treated with both oral and intravenous antibiotics (*i.e.*,
aztreonam, tobramycin, levofloxacin), and anti-inflammatory drugs (*i.e.*, high-doses
ibuprofen <sup>7</sup>).

70 Yet, to enter into the systemic circulation, drugs administered by the oral, pulmonary, 71 nasal or rectal routes, need come in contact and subsequently cross the epithelium in 72 order to reach the capillary circuitry in the lamina propria. Thus, effective drugs 73 administered by these routs should harbor the ability to transverse mucus barriers to 74 be pharmacologically active. In the context of cystic fibrosis, the pathological mucus can 75 strongly limit the absorption of drugs that do not exhibit these difficulties under normal 76 physiological conditions. Also, the pathological CF mucus, is characterized by a reduced 77 mesh size (60-300 nm)<sup>8</sup> with respect to physiological mucus (497-503 nm)<sup>9</sup>. Two main 78 mechanisms are expected to affect drug diffusion through mucus: steric and interactive 79 filtering (Fig. 1). Oligomers of secreted mucins connect with each other creating a 80 complex network that filters molecules bigger than the size of the mesh spacing 81 between mucin fibers <sup>10</sup> (steric filter). Molecules small enough to penetrate the mucin 82 mesh are subjected to the interactive filter which is mainly governed by the structural 83 complexity of mucins. On the highly glycosylated hydrophilic regions, negative charges 84 are exposed due to the presence of sialic acid. On these substrates, hydrogen bonding 85 and electrostatic interactions can be established with polar and hydrophilic molecules. 86 But not the entire peptide core of mucins is glycosylated; cysteine-rich domains are 87 glycans free and usually folds into hydrophobic regions on which lipophilic molecules 88 can attach. And yet, mucin is just one of the components of mucus. Other substances 89 such as lipids, antimicrobial peptides (defensins, histatins, collectins etc.,), lytic 90 enzymes (lysozyme) and antibodies (IgA and IgG) are components of mucus as well, 91 and each one of them has the potential to interact with drugs.




Figure 1. The steric and interactive barriers of mucus. Drugs larger than the mesh spacing between mucin
fibers are stacked within mucus because too big to cross the mucus mesh. Similarly, drugs smaller than the
mesh but able to interact with mucus components are equally retained by mucus. On the contrary, particles
that are small enough and relatively inert to any of the mucus component can freely diffuse through the mucus
layer and eventually absorbed.

99

100 The importance of developing in vitro models able to model both the biological 101 structure and functions of pulmonary mucus is increasingly gaining awareness in 102 modern drug discovery. Today, the most popular in vitro models for assessing 103 permeability/absorption of drugs, are those based on artificial membranes, such as 104 parallel artificial membrane permeability assay (PAMPA) <sup>11</sup>, systems based on cells, 105 such as Caco-2<sup>12</sup> and MDCK<sup>13</sup>; and systems based on site-specific tissues<sup>14</sup>. Notably, 106 none of them takes mucus specifically into account. In the last years, a variety of mucus 107 models have been proposed <sup>15</sup>. The proposed models include gastrointestinal mucin-108 based solutions<sup>16,17</sup>, reconstituted oral mucus gels <sup>18</sup>, multilayered polyelectrolyte films 109 <sup>19</sup>, and *in vitro* cell cultures models incorporating airway mucus or mucus-producing 110 cells <sup>20</sup>. Falavigna *et al.* developed a mucus phospholipid vesicle-based permeation 111 assay that has been used for permeability screening of drugs and formulations <sup>21</sup>.

112Recently we developed an *in vitro* mucus model which simplifies mucus complexity by113mimicking the chemical composition, structural features and viscoelastic properties of114pathological CF mucus <sup>22</sup>. The viscoelastic property of CF mucus is achieved by taking115advantage of the internal gelation of alginate in the presence of calcium ions. Alginate116is an extracellular exopolysaccharide component of mucoid *P. aeruginosa*, a hallmark of117CF infection, and has been shown to protect bacteria against certain antibiotics as well

118 as escape the immune system <sup>23,24</sup>. To reproduce the interactive and steric filters of CF 119 mucus we used commercially available unpurified mucin type III from porcine stomach. 120 One may argue that commercial mucins are different in terms of structure and 121 viscoelastic properties respect to native mucins. Indeed, it has been established that 122 commercial mucins fail to form hydrogels at acidic pH, are only partially purified and 123 are inferior in inhibiting virus infection compared to natively purified mucins obtained 124 in lab <sup>25</sup>. However, the purpose of our mucus model is to have an easy to use and easy 125 to reproduce *in vitro* mucus model suitable for average throughput screening (HTS) 126 applications. Thus, even if in lab extracted mucins are qualitatively superior to 127 commercial mucins, the time consuming and expensive procedures of purification, 128 extraction and concentration at laboratory level are not adapted for HTS purposes.

129 In this study, we aimed at expanding the applicability and relevance of our in vitro cystic 130 fibrosis pathological mucus model. To reach this aim we addressed the following goals: 131 (i) selected 45 commercially available drugs maximizing physicochemical variability; 132 (ii) performed PAMPA measurements in the absence of mucus and assessed the 133 physicochemical determinants of apparent permeability  $(P_{app})$ ; (iii) we coupled the 134 developed mucus model with PAMPA to mimic in vitro cystic fibrosis airway mucosal 135 surface. The permeability in the presence of mucus was compared with the  $P_{app}$ 136 obtained in the absence of mucus; (iv) eventually, permeability with cystic fibrosis 137 sputum was measured to support the conclusion drawn from the *in vitro* model herein 138 presented.

Overall, this study highlights the challenging of reproducing *in vitro* the complexity of cystic fibrosis dysfunctional mucus. While PAMPA could be a reasonable model to mimic permeability through cellular membrane, we have shown that it is a too simplistic model to mimic the diffusion across pathological CF mucus. As a first screening tool of poorly permeable molecules, a fully tunable in vitro mucus model, easy to reproduce, and mimicking both the composition and the rheological properties of CF mucus, could be of high usefulness in the early drug discovery.

- 146
- 147

#### 2. Experimental section

- 148
- 149

#### 2.1. Computational Part

The drug SMILES codes were retrieved from DrugBank <sup>26</sup>. The csv file of the approved
drugs was downloaded from DrugBank (last update on 3 January 2021). The csv file
was transformed in xlsx file using Microsoft Excel (v. 16.43). The SMILES of CFTR<sub>inh</sub>172, which is a non-commercial drug acting as an inhibitor of the CFTR protein, was

retrieved from PubChem<sup>27</sup>. Molecular properties were calculated with DataWarrior (ver. 5.5.0, openmolecules.org) and include physico-chemical properties, druglikeness related properties, various atom and ring counts, molecular shape, flexibility as well as functional groups (Table S2). The molecular charge at pH 7.4 was retrieved from

158 MarvinSketch (Marvin 20.20, 2020, ChemAxon).

The dataset was analyzed with the Principal Component Analysis (PCA) tool
implemented in DataWarrior. The correlation matrix of the descriptors was calculated
using DataWarrior and represented as a heatmap.

162

#### 163 2.2. Materials

164 Mucin from porcine stomach (PGM Type III, bound sialic acid 0.5-1.5%, partially 165 purified powder), sodium salt of alginic acid, calcium carbonate, D-(+)-gluconic acid  $\delta$ -166 lactone  $\geq$  99.0% and sodium chloride used to develop the airway mucus model were all 167 purchased from Merck (Germany). Permeability experiments were carried out on 168 Corning<sup>®</sup> Gentest<sup>™</sup> Pre-coated PAMPA, 353015, USA plates. Millipore<sup>®</sup> grade water 169 (resistivity: 18.2 MΩ cm at 25 °C) was obtained from an in-house Millipore® system. 170 Acetonitrile, ammonium acetate and DMSO were of the highest available grade and 171 purchased from Sigma Aldrich. The drugs used in this study were all commercially 172 available (Fig. S1). Stock solutions were prepared in DMSO and stored at 4 °C.

173

#### **174 2.3. Mucus model**

175 The herein used mucus model can be exploited as a platform for drug diffusion either 176 for cystic fibrosis mucus or other mucus-related disorders such as mucus of chronic 177 obstructive pulmonary disease, which unveils its potential for a wide range of 178 applications in drug discovery. The mucus model was prepared as previously described 179 <sup>22</sup>. Briefly, a 21 mg/mL alginate sodium salt solution was dissolved in a 16.3 mg/mL 180 NaCl solution, under slow magnetic agitation. In parallel, a 43.7 mg/mL mucin 181 suspension was prepared in mQ water and left under slow agitation over-night. The 182 alginate and mucin solutions were mixed at a 1:4 proportion using two jointed luer-183 lock syringes. Then, the alginate and mucin suspension were mixed with a suspension 184 of 7 mg/mL CaCO<sub>3</sub> prepared in 16.3 mg/mL NaCl solution. In the last step, a 70 mg/mL 185 GDL solution was freshly prepared in 16.3 mg/mL NaCl and mixed with the previously 186 prepared suspension (alginate, mucin and CaCO<sub>3</sub>) at a proportion of 1:6. Finally, 40 µL 187 of the mucus model were pipetted directly over the PAMPA membrane in the donor 188 compartment, producing a hydrogel of approximately 500 µm in thickness. The donor 189 plate of the PAMPA was then carefully shacked to uniformly distribute the volume of mucus over the entire well surface and to get rid of any air bubbles. Afterwards, the
mucus within the plate was left to crosslink for 24 h before the addition of drug
solutions. Throughout the time course of the permeability experiment, the CF mucus
model remained stable with respect to weight and thickness variations. In fact, we
previously determined that after 6h of incubation in an aqueous medium, mucus
undergoes a thickness variation below 10% which was considered acceptable for our
experimental purpose<sup>22</sup>.

197

#### 198 2.4. PAMPA assay

199 The apparent permeability  $(P_{app})$  and the effect of mucus on permeability were 200 experimentally determined through PAMPA and mucus-PAMPA assays, respectively. 201 Stock solutions of all drugs were prepared in DMSO at a concentration of 10 mg/mL. 202 Donor solutions of drugs were prepared in PBS (10 mM, pH 7.4, 5% DMSO) at a 203 concentration between 100 to 500 µM, depending on the drugs' specific solubility. Each 204 donor well was filled with 200 µL of drug solution, while the acceptor wells were filled 205 with 300 µL of PBS. The donor plate was then placed on top of the acceptor plate, so the 206 artificial membrane was in contact with the buffer solution below. A lid was placed on 207 top of the donor plate and the whole PAMPA plate was incubated at room temperature 208 for 5 h. At the end of the incubation period, the plates were separated, and the volume 209 of the acceptor wells was collected. Concentrations of drugs in each acceptor well were 210 quantified either by HPLC-UV or HPLC-MS. The apparent permeability coefficient ( $P_{app}$ ) 211 was expressed using equation 1 derived from Fick's law<sup>28</sup> for steady state conditions:

212  $P_{app} = \frac{dQ/dt}{C_0 \times A}$ (Eq. 1)

where dQ is the quantity of drug expressed as moles permeated into acceptor compartment at time t (18,000 sec),  $C_0$  is the initial concentration in the donor well and A is the area of the well membrane (0.3 cm<sup>2</sup>). The  $P_{app}$  was used as an average of all the measures.

217 The same PAMPA experimental setup was adopted when assessing the effect of 218 individual components of mucus. In particular, we evaluated how the PGM, the NaCl, 219 the alginate hydrogel and calcium impact on permeability. For this purpose, the passive 220 diffusion was measured in the presence of each one of these chemicals. Each of which, 221 were individually added in the donor compartment of the PAMPA. In brief, 40  $\mu$ L of the 222 alginate gel were deposited over the phospholipid membrane of the donor 223 compartment prior the addition of drug solution. The influence of PGM was assessed by 224 filling the donors with a suspension of drug containing 4.16 mg/mL of PGM (the PGM 225 concentration donor compartment). Similarly, drug donor solutions containing 1.67

mM CaCl<sub>2</sub> or 20 mM NaCl were used when investigating the impact of calcium and NaCl
 over permeability.

228

229

#### 2.5. Cystic fibrosis sputum

230 Sputum collected from cystic fibrosis patients was used as a model of complex 231 biological matrix representative of CF mucus. We measured the permeability of some 232 of the drugs of our dataset using the CF sputum – PAMPA system and compared the 233 results with the permeability obtained in the presence of our mucus model. Sputum 234 samples were a kind concession of Prof. A. Ghigo from the Department of Molecular 235 Biotechnology of University of Turin. Spontaneously expectorated sputum was 236 collected into sterile containers and was processed as described by Oriano et al. 29. 237 Briefly, samples were processed getting first rid of saliva. Then, samples were diluted 238 8x in PBS, vortexed until sputum dissolution and centrifuged for 15 min at 3000 g. Forty 239  $\mu$ L of sputum were deposited over the PAMPA membrane in the bottom of the top plate, 240 and eventually 200 µL of drug solution were inserted over the layer of CF sputum, while 241 300 µL of PBS were inserted into the bottom plate of the PAMPA. The two plates were 242 coupled and incubated for 5h. At the end of the 5h the plates were splitted and the 243 amount of drug diffused into the bottom plate was quantified. Similarly, to test the effect 244 of calcium over the permeability of the drug, we formed drug-calcium complexes by 245 dissolving the drug into PBS containing calcium at the same concentration present in 246 the cystic fibrosis mucus model. The permeability of calcium-drug complexes was 247 measured through the CF sputum PAMPA as previously described.

248 249

#### 2.6. Quantification

250 All compounds, except ebselen, benzoic acid and 3-aminophenol, were analyzed and 251 quantified by HPLC-MS/MS using a Varian HPLC equipped with a 410 autosampler and 252 an Ascentis C18 column (10 cm x 2.1 mm, 3 µm). Gradient mobile phases composed of 253 acetonitrile and water 0.1% formic acid or ammonium acetate 5 mM pH 6.6 as organic 254 and aqueous phase respectively were pumped at a flow rate of 200  $\mu L/min.$  A flow of 255 200 µL/min and an injection volume of 10 µL were used. Compounds were detected on 256 a Varian 320 MS TQ Mass Spectrometer equipped with an electrospray ionization (ESI) 257 source operating in positive or negative mode, depending on drugs' method. The 258 detector was used in multiple reaction monitoring (MRM) mode and the transitions of 259 each drug are reported in Table S1.

260 Ebselen, benzoic acid and 3-aminophenol were quantified on a HPLC Varian ProStar261 equipped with a 410 autosampler and a PDA 335 LC Detector. The analysis was

262 conducted on a IAM column (Regis, 10 cm x 4.6 cm 10 μm packing 300 Å pore size)
263 using ammonium acetate and acetonitrile as aqueous and organic mobile phase,
264 respectively. The flow rate was 1 mL/min.

265 266

#### 2.7. Statistical analysis

267A minimum of 4 replicates were conducted for each compound on each experimental268method (with or without the mucus model), some of whom repeated also on different269PAMPA plates. Results are expressed as mean  $\pm$  SD. Student's t-test was applied to270detect statistical significance between the permeability recorded with and without271mucus. A p<0.05 was considered to be a statistically significant difference.</td>

- 272
- 273 274

275

#### 3. Results and discussion

#### 3.1. Dataset selection: assessment of chemical heterogeneity

We included in our dataset a number of anti-inflammatory (ibuprofen, dexamethasone)
and antibacterial drugs (tobramycin, ceftazidime, aztreonam, ciprofloxacin,
tetracycline) commonly employed in the cystic fibrosis therapy regimes. To properly
evaluate the performances of our CF mucus model, we expanded the dataset up to 45
compounds considering it a reasonable number of drugs to be investigated, with good
variability in terms of chemical properties (see below).

282 To assess the distribution of our dataset within the entire drug chemical space, at first, 283 we downloaded the DrugBank database of approved drugs. From DrugBank's database 284 we retrieved the SMILES code for each compound and used them to calculate molecular 285 descriptors (see Methods, Table S2). Using drugs as observations and the selected 286 molecular descriptors as variables, we then computed a principal component analysis 287 (PCA). The drugs within our dataset are small molecules therefore, focus was pointed 288 on compounds of total molecular weight <1,000 Da (yellow dots in Fig. 2A). The 289 variance explained by PC1 and PC2 using 30 molecular descriptors is about 60%. In the 290 score plot defined by PC1 and PC2 is possible to appreciate a good distribution of the 291 tested drugs within the chemical space (red dots in Fig 2A).

To assess chemical variability within our dataset we also evaluated the Lipinski's rule of five (Ro5) molecular descriptors distribution (the number of the hydrogen bond donors (HBD), the number of the hydrogen bond acceptors (HBA), the molecular mass (MW), and the octanol-water partition coefficient (LogP)). Figure 2B shows that all the descriptors categories are well represented by the dataset,




Figure 2. (A) Distribution of the tested drugs (red dots) within the DrugBank database of approved drugs
 (yellow dots) having total molecular weight ≤1000 Da. (B) Classification and distribution based on Lipinski's
 rule of five (B). Compounds that violate the Ro5 for each molecular descriptor are represented by the red
 bars.

#### 3.2. Validation of the permeability setup to measure P<sub>app</sub>

298


303 304

305 Before evaluating the effect of mucus on drug permeability, we determined and 306 validated permeability in the absence of mucus through an artificial cellular membrane 307 since our method differs from the standard PAMPA protocol. In fact. in our setup 308 (modified setup), mucus was placed over the PAMPA membrane (a filter plate pre-309 coated with structured layers of phospholipids). in the top well as is the only way to 310 have a physical support that can sustain mucus. Thus, diffusion takes place from the top 311 to bottom well and drug has been quantified only in the acceptor compartment (bottom 312 well).

Data obtained with our original set-up (Table 1) were firstly validated using a subset of compounds taken from the paper of Chen et al.,<sup>30</sup> (Table S3 and Fig. S2) using the same artificial membrane (r<sup>2</sup>=0.610, Fig. S2) . Notably, compounds as propranolol and caffeine known for being high permeable<sup>31,32</sup> could clearly be discriminated from low permeable compounds.

318 Then we determined which molecular descriptors mostly govern permeability in our 319 system. To do that a correlation matrix between apparent permeability  $(P_{app})$  and a pool 320 of molecular descriptors (Fig. S3 and Methods) were calculated. The highest correlation 321  $(r^2 = 0.303)$  was found to exist with topological polar surface area (TPSA, the surface 322 sum over all polar atoms or molecules, mainly oxygen and nitrogen, also including their 323 attached hydrogen atoms) and in minor extent with hydrogen bond donor and acceptor 324 groups (HBD and HBA). In particular, the higher the TPSA, the lower the *P*<sub>app</sub>. This is in 325 line with the literature <sup>33</sup> and again confirms the reliability of our system.


- 326 Finally, we verified whether TPSA can distinguish high from low permeable 327 compounds. Although a definitive threshold is missing, in the standard PAMPA setup 328 the P<sub>app</sub> value for distinguishing low from highly permeable compounds is frequently 329 set at  $1.5 \times 10^{-6}$  cm/s  $^{30}$ . However, in a modified setup (diffusion from the top to the 330 bottom well) the permeability threshold is higher  $^{34}$   $^{35}$ . Here we used 4  $\times$  10<sup>-6</sup> cm/s and 331  $1 \times 10^{-6}$  cm/s to distinguish high, medium and low permeable molecules. Figure 3B shows that TPSA values of 140 Å<sup>2</sup> <sup>36</sup>. and of 75 Å<sup>2</sup> <sup>37,38</sup> are able to predict permeability 332 333 class of the investigated dataset.
- In addition to the discrimination based on the total polar surface area, we plotted the high and low permeable compounds in the chemical space based on their chemical properties. For this purpose, we computed a principal component analysis using as variables the molecular descriptors calculated from DataWarrior. Indeed, we can observe a good separation of the two groups on the first principal component (See Fig.
- 339 S4 A-C).



342Figure 3. Classification in high and low permeable compounds (A) of the tested drugs based on the343determined apparent permeability ( $P_{app}$ ) Dataset grouping within permeability categories (B): permeability344classification: green = high, yellow = medium, red = low. The  $P_{app}$  threshold high-medium and medium-low345permeable compounds was set at 4 and  $1 \times 10^{-6}$ , respectively. TPSA threshold between high-medium and346medium-low permeable compounds was set at 75 and 140 Å<sup>2</sup>, respectively. The number beneath each dot347refers to drug name (see Fig. S1 and Table 2).

- **349** Overall, we validated the goodness of the experimentally determined  $P_{app}$  in the absence
- **350** of mucus and confirmed that the  $P_{app}$  values can be used as benchmark when assessing
- the effect of mucus in the mucus-PAMPA system.

# 353 3.3. Permeation studies in the presence of a mucus model 354 The mucus model was adapted to the PAMPA plate by directly pipetting it on top of the 355 phospholipid membrane in the donor compartment. As all the wet epithelia of the 356 human body are covered by mucus, drugs administered by oral or pulmonary routes 357 have to cross both the mucus layer and the cellular membrane to be absorbed, and thus 358 to be effective. With our adapted mucus-PAMPA system we are expecting to be able to 359 mimic *in vitro* the interface at mucosal surfaces. (Fig. 4).





366

362
363 Figure 4. Comparison between PAMPA and mucus-PAMPA system. On top the upper view of the PAMPA
364 wells, on the bottom the lateral view of the donor and acceptor compartments. Dashed lines highlight the
365 mucus layer and the phospholipid membrane (PM).

367The effect of mucus was measured in terms of variations of permeability and was368considered statistically significant only if the *p*-value between the means of the two369groups (PAMPA and mucus-PAMPA) was <0.05. A summary of the  $P_{app}$  with and without370mucus is reported in Table 1, while the detail of each drug tested is reported in SI (Fig.371S6).

372

**373Table 1.** Summary of the  $P_{app}$  recorded on PAMPA and the effect the mucus model played over permeability**374**with the respective  $P_{app}$  variations. The terms *increased / decreased* are used only if the difference on**375**permeability is statistically significant. Student's t-test was applied to detect statistical significance between

the permeability recorded with and without mucus. A p<0.05 was considered to be a statistically significant</li>difference.

378

Nr	Compound	MW (g/mol)	Lipophilicity	P <sub>app</sub> PAMPA (± SD) ×10 <sup>-6</sup> [cm/s]	P <sub>app</sub> Mucus-PAMPA (± SD) ×10 <sup>°</sup> <sup>6</sup> [cm/s]	Effect of mucus on P <sub>app</sub>
1	Propranolol	259.3	medium	12.56 (± 2.9)	2.84 (± 1.4)	Decreased (-1)
5	Ebselen	274.2	low	4.01 (± 0.6)	1.82 (± 0.8)	Decreased (-1)
8	Oseltamivir	312.4	medium	1.30 (± 0.3)	0.32 (± 0.1)	Decreased (-1)
11	Umifenovir	477.4	medium	1.03 (± 0.1)	0.18 (± 0.0)	Decreased (-1)
12	Zanamivir	332.3	medium	0.42 (± 0.2)	0.02 (± 0.0)	Decreased (-1)
13	Levofloxacin	361.4	low	5.94 (± 2.7)	0.00 (± 0.0)	Decreased (-1)
14	CFTRinh-172	409.4	medium	7.35 (± 2.9)	3.84 (± 1.2)	Decreased (-1)
15	Verapamil	454.6	low	8.57 (± 2.0)	0.53 (± 0.5)	Decreased (-1)
16	3-aminophenol	109.1	low	8.28 (± 1.4)	0.74 (± 0.6)	Decreased (-1)
17	Amlodipine	408.9	medium	6.60 (± 1.9)	0.00 (± 0.0)	Decreased (-1)
18	Amitriptyline	277.4	high	5.80 (± 1.2)	0.00 (± 0.0)	Decreased (-1)
19	Procaine	236.3	low	4.00 (± 1.0)	$0.00 (\pm 0.0)$	Decreased (-1)
20	Caffeine	194.2	low	12.70 (± 3.5)	6.43 (± 4.2)	Decreased (-1)
25	Tetracycline	444.4	high	1.22 (± 1.0)	0.00 (± 0.0)	Decreased (-1)
26	Ritonavir	721.0	high	1.60 (± 0.4)	0.61 (± 0.2)	Decreased (-1)
31	Salbutamol	239.3	low	0.04 (± 0.0)	0.01 (± 0.0)	Decreased (-1)
34	Lumacaftor	452.4	medium	6.64 (± 0.8)	5.40 (± 0.3)	Decreased (-1)
36	Lidocaine	234.3	high	9.47 (± 0.3)	0.05 (± 0.1)	Decreased (-1)
38	GUDCA	449.6	medium	0.76 (± 0.3)	0.22 (± 0.3)	Decreased (-1)
42	Quinine	324.4	low	9.54 (± 1.0)	6.66 (± 0.6)	Decreased (-1)
3	Camostat	398.4	medium	3.04 (± 1.3)	3.28 (± 2.9)	None (0)
4	Dexamethasone	392.5	medium	0.85 (± 0.4)	0.46 (± 0.4)	None (0)
6	Favipiravir	157.1	high	2.44 (± 1.1)	3.17 (± 1.3)	None (0)
7	Indinavir	613.8		1.22 (± 0.3)	0.94 (± 0.7)	None (0)
9	Remdesivir	602.6	low	1.86 (± 1.6)	1.63 (± 1.5)	None (0)
10	Saquinavir	670.9	high	0.08 (± 0.1)	0.10 (± 0.1)	None (0)
	Ampicillin	349.4		2.29 (± 0.6)	1.34 (± 0.7)	None (0)
	Ceftazidime	546.6		0.93 (± 0.5)	1.14 (± 1.0)	None (0)
29	Ciprofloxacin	331.3	low	0.54 (± 0.3)	0.31 (± 0.3)	None (0)
	Rifampicin	823.0		0.61 (± 0.4)	0.19 (± 0.1)	None (0)
	Aztreonam	435.4		2.45 (± 1.5)	1.64 (± 0.6)	None (0)
	Cefuroxime	424.4		0.87 (± 0.7)	0.16 (± 0.2)	None (0)
	Valsartan	435.5	low	0.56 (± 0.5)	0.44 (± 0.5)	None (0)
	TUDCA	499.7		0.17 (± 0.2)	0.04 (± 0.1)	None (0)
	Tobramycin		high	0.19 (± 0.0)	0.25 (± 0.1)	None (0)
	Ibuprofen	206.3	medium	9.09 (± 1.4)	10.33 (± 1.2)	None (0)
	Antipyrine	188.2	medium	5.75 (± 1.7)	6.19 (± 2.6)	None (0)
	Baricitinib	371.4		0.99 (± 0.5)	2.68 (± 2.1)	Increased (+1)
	Naproxen	230.3		9.57 (± 3.9)	22.02 (± 6.1)	Increased (+1)
	Piroxicam	331.4		3.15 (± 0.8)	6.63 (± 0.1)	Increased (+1)
	Diclofenac		medium	4.03 (± 0.2)	5.06 (± 0.1)	Increased (+1)
	Indomethacin	357.8	medium	1.32 (± 0.3)	2.54 (± 0.9)	Increased (+1)
	Acetaminophen	151.2	medium	$0.99 (\pm 0.1)$	6.22 (± 0.9)	Increased (+1)
	Benzoic acid	131.2	medium	4.06 (± 0.9)	9.91 (± 0.9)	Increased (+1)
	Ketoprofen	254.3		. ,	. ,	Increased (+1)
44	Ketopioien	234.3	10 W	4.04 (± 0.7)	9.24 (± 1.2)	mereaseu (+1)

379 380


Three kinds of mucus-induced effects were observed (Table 1 and Fig. 5A): a) in the presence of mucus, 44% of drugs showed a decreased permeability, b) 38% had no statistically significant variation, and c) 18% had an increased permeability. Among the compounds which diffusion was reduced by mucus, we cannot outline any dependency on drugs lipophilicity. In fact, mucus reduced the permeability of both hydrophilic and lipophilic drugs which is in agreement with what found by Boegh *et al.*, <sup>18</sup> using a biosimilar mucus on Caco-2 cells, and Falavigna *et al.*, <sup>21</sup> with a mucin-PVPA system.

388 Data suggests that the CF pathological mucus model did not act as a mere physical 389 barrier. It behaves as an interactive filter as different structures interacted differently 390 with mucus. This can be attributed to low affinity interactions taking place during the 391 diffusion process across the mucus layer and is mostly dependent on the structure of 392 mucins. In fact, due to the complex architecture of mucins, hydrophobic drugs can be 393 retained by the naked domains of the peptide core of mucin, while hydrophilic drugs 394 can entangle with the branched oligosaccharides. In addition to the interactive filter 395 orchestrated by mucins through hydrophobic, electrostatic and hydrogen bonding 396 interactions, mucins can hinder the diffusion of xenobiotics also through a size filtering 397 mechanism dependent on the mucin mesh. To estimate the mesh size of our mucus 398 model we applied the generalized Maxwell model (GMM) as described in our previous 399 work<sup>22</sup>. The estimated mesh size was  $54.7 \pm 5.35$  nm which is in good agreement with 400 what reported in the literature for pathological mucus. Considering that our dataset is 401 composed of only small molecules, thus much smaller than the mesh of our mucus 402 model, we think the steric filter had a minor impact on drug diffusion.

403 Once we had assessed the effect that mucus plays on the *P*<sub>app</sub> (*i.e.*, decreased, no effect, 404 increased) of each compound, we then wanted to quantitatively compute the activity of 405 mucus. Thus, we assigned numerical values to each effect, particularly -1, 0, +1 when 406 the permeability was decreased, unvaried and increased, respectively. The effect of 407 mucus over permeability varies without any apparent relation to any of the molecular 408 descriptors selected, as shown by the correlation matrix (Fig. S3), In fact, the relation 409 between the  $P_{app}$  and TPSA registered in the absence of mucus does not hold true 410 anymore. If we previously could correctly predict the permeability of almost 80% of the 411 tested compounds, after the addition of mucus we see that only 53% of the molecules 412 have their permeability correctly predicted (Fig. 5B). For instance, amitriptyline 413 (compound nr. 18) in the absence of mucus belongs to the high permeable group as it 414 has low TPSA and high *P*<sub>app</sub>; in contrast, the presence of mucus strongly decreases its 415 permeability. Amitriptyline is a highly lipophilic drug though being positively charged 416 at pH 7.4. Such a reduction of permeability that we observe, may be the result of a 417 combined retention due to interactions with the lipophilic domains and the negatively 418 charged glycans of mucin. As amitriptyline, many other drugs have their permeability 419 decreased (see Table 1 and Fig. 5).

With the drug diffusion studies on the mucus-PAMPA system we show that the
pathologic cystic fibrosis mucus model can strongly influence the permeability of drugs.
Theoretically, if the observed effects would have been similar for all compounds, one
could reasonably state that the rate-limiting factor could be the longer diffusive

424 pathway when in the presence of mucus. Though, this hypothesis should be discarded
425 as we have found that for some drugs the presence of the pathological mucus model
426 may increase permeability. These results are discussed in the next session.



429Figure 5. The impact of mucus over permeability. (A) The permeability recorded in the presence of mucus.430(B) Grouping within permeability categories of the 45 compounds tested (permeability classification: green431= high, yellow = medium, red = low). The  $P_{app}$  threshold of high-medium and medium-low is set at 4 and 1 ×43210-6, respectively. TPSA threshold of high-medium and medium-low is set at 75 and 140 Å<sup>2</sup>, respectively. The433number beneath each dot refers to drug name (see Fig. S1 and Table 2). As an example, focus is pointed on434the variation of permeability of amitriptyline (nr 18, blue dot) in the absence and presence of mucus.


#### 436 3.4. On the increased permeability in the presence of pathological mucus

437 We expected the mucus model to reduce or have no effect on the permeability of drugs. 438 Figure 5A clearly reports that some of the compounds we tested (such as naproxen) 439 presented a higher permeability in the presence of mucus than in its absence. Among 440 the tested drugs, 18% (baricitinib, naproxen, piroxicam, diclofenac, indomethacin, 441 acetaminophen, benzoic acid, ketoprofen) had a significant increase of permeability in 442 the presence of mucus. In respect to the entire dataset, the increased-permeability 443 group share some chemical-physical properties; they are relatively small molecules 444  $(MW < 380 \text{ Da}, \text{Total Surface Area} < 270 \text{ Å}^2)$ , lipophilic (cLogP > 1), have medium-low 445 polarity (PSA<130  $Å^2$ ), and 6 out of 8 are negatively charged at pH 7.4.

- 446
- 447 448

### 3.4.1. The role of the mucus components in the enhancement of permeability

449 To isolate the driving force of the increased diffusion rate observed in the presence of 450 our mucus model, we disassembled the mucus and measured the permeability of 451 naproxen in the presence of each one of the components of mucus. For this purpose, we 452 selected naproxen as a model drug as it is the most remarkable compound for which 453 the permeability increases with mucus (Fig S6). The main components of our mucus 454 model are PGM which is used to mimic the composition of CF mucus; alginate because 455 it is produced by mucoid *P. aeruginosa* infecting the CF mucus; CaCO<sub>3</sub> used to crosslink 456 alginate, and NaCl necessary to reproduce the salinity of CF mucus. Thus, we performed 457 a PAMPA assay where naproxen solutions were prepared in PBS buffer containing 458 either PGM, or NaCl or calcium in the same concentrations used in the mucus model. In 459 the case of the alginate gel, it was deposited on the bottom of the top compartment of 460 the PAMPA the day before the experiment to allow alginate to crosslink. (top of Fig. 6). 461 We observed that while the diffusion rate in the presence of PGM or NaCl did not 462 undergo major variations, in the other two systems (*i.e.*, the alginate gel and CaCl<sub>2</sub>) a 463 net increase of permeability was obtained. It is noteworthy to remind that the alginate 464 gel contains calcium as it is necessary to crosslink the alginate solution hence, to form 465 the hydrogel matrix. The most probable scenario explaining such an activity could rely 466 on ion-pairing as it is known that Ca<sup>2+</sup> ions have a strong affinity for O, N or F atoms 467 because the metal act as Lewis acid and thus form complexes with many ligands <sup>39</sup>. The 468 binding of calcium ions is highly selective and can form asymmetric complexes that 469 consist of a large radius.



472 Figure 6. (A) The experimental setup used to isolate the effect of each one of the components of mucus. (B)
473 the permeability of naproxen recorded in the presence of individual components of mucus.


474 475

#### 3.4.2. The role of calcium

476 Once we isolated Ca<sup>2+</sup> as the reason for the increased permeability, we then wanted to understand if this phenomenon is dependent on the negative charge borne by some of 477 478 the drugs. Tests were repeated with ketoprofen and indomethacin as anions on which 479 mucus increased their respective permeabilities, as well as CFTR<sub>inh</sub>-172 and cefuroxime 480 as anions with reduced and unvaried permeability (negative controls) in the presence 481 of mucus, respectively. For naproxen, ketoprofen and indomethacin, permeability rises 482 in presence of the alginate hydrogel and gets even higher in presence of the only CaCl<sub>2</sub> 483 (Fig. 7A). It has been reported that these three drugs and other non-steroidal anti-484 inflammatory agents (NSAIDs) can form complexes with calcium<sup>39-41</sup>. Interestingly, 485 Ogiso and colleagues reports that the absorption of indomethacin calcium salt on rat 486 abdominal skin is significantly higher than that from indomethacin alone  $4^{1}$ . When 487 forming complexes with calcium, naproxen, ketoprofen and indomethacin are 488 neutralized; they shift from a negatively charged form to exhibiting no relative charge. 489 The neutralization implies a decrease of polarity in favor of lipophilicity which we think 490 it actually favors the diffusion through the artificial phospholipid membrane of PAMPA 491 (Fig. 7B). It should be noted, when drug-calcium complexes are formed, the molecular 492 descriptors are completely different from that of the free drugs and cannot be easily 493 calculated. In addition, the higher permeability observed with CaCl<sub>2</sub> could be due to 494 larger availability of free Ca<sup>2+</sup> in solution. In fact, in the system containing alginate, 495 despite having the same Ca<sup>2+</sup> concentration, part of it is not available because of the ion 496 crosslinking with alginate. On the contrary, we observe that the permeability of 497 CFTR<sub>inh</sub>-172 and cefuroxime is not influenced by the presence of calcium, even though 498 if they are also considered anionic drugs.

499 Overall, we hypothesized that drug-calcium salts have higher passive diffusion rates
500 through the PAMPA phospholipid artificial membrane with respect to the not501 complexed drug. However, the formation of calcium salts is not merely dependent on
502 the negative charge as not all the anionic drugs included in the dataset enhanced
503 permeability.

504



508

509

- 510
- 511 512
- 513

#### 3.4.3. CF patient sputum validation

514 In the next step we wanted to understand if the results recorded in the presence of our 515 mucus model can be reproduced using a more complex biological matrix to mimic CF 516 sputum. For this purpose, we employed CF sputum as it is often considered a rough ex 517 vivo model of CF mucus, and we measured the permeability of naproxen, ketoprofen 518 and indomethacin. In fact, a hallmark of diseases such as CF, COPD and bronchiectasis 519 is the excessive production of sputum. As a consequence of the altered physico-520 chemical properties, the diseased sputum contains higher concentrations of 521 inflammatory mediators, lytic enzymes (*i.e.*, neutrophil elastase) and bacterial 522 colonization. However, due to the high variability among patients, which depends on 523 the diseases stage, the measurements performed with CF sputum may have a low 524 reproducibility.

Figure 7. The effect of calcium over the permeability of some anions at pH 7.4. (A) Naproxen, ketoprofen and

indomethacin have higher diffusion rates when calcium is present. CFTRinh-172 and cefuroxime do not

undergo permeability variations in the presence of calcium. Two-way ANOVA comparing each group mean


with the mean of each other group was used to compute statistical analysis. (B) Schematic representation of

the calcium-naproxen complex and the passive diffusive mechanism through mucus-PAMPA system.

525 Given the high concentration of calcium in our mucus model we wanted to find out if 526 the permeability of some negatively charged drugs results overestimated when using 527 the mucus model developed by us. As expected, in the presence of the CF sputum the 528 permeability of naproxen, ketoprofen and indomethacin was decreased, even though 529 the variation was not statistically significant (FIG. 8A). Such a reduction could be the 530 result of interactions with neutrophil elastase and proteases also present at high 531 concentrations in the CF sputum. Mandel et al.42, reported higher concentrations of 532 calcium (136  $\pm$  33  $\mu$ g/mL) in submaxillary saliva of CF patients with respect to healthy 533 people (71  $\pm$  19 µg/mL). Based on these values, we can estimate almost a 10x higher 534 concentration of calcium in our model than that of the *in vivo* scenario. Therefore, we 535 can speculate that the permeability of some negatively charged drugs might be 536 overestimated with our CF mucus model.

537 Despite this, we establish evidence indicating that some negatively charged drugs can 538 form calcium-drug salts which have higher diffusion rates on PAMPA respect to the free 539 drugs. In terms of permeability, these salts might be less affected by the barrier effect 540 of mucus. Thus, we wondered if this mechanism can be exploited to increase the 541 permeability of naproxen, ketoprofen and indomethacin through CF sputum. For this 542 purpose, we repeated the permeability test through CF sputum, this time suspending 543 the drugs into PBS containing calcium. As can be seen from Fig. 8B, the permeability of all of the three drugs was significantly higher for the samples containing calcium. This
is likely a consequence of the formation of calcium complexes which increased more
than twice the permeability of the drugs through CF sputum.

547 Even though the concentration of calcium in the CF mucus is reported to be lower than
548 that of our mucus model, it is still clear the impact that calcium can play on permeability.
549 Drug calcium salts might have better biological activities and should be considered
550 when formulating drugs. For instance, high-dose ibuprofen taken constantly for years
551 has shown to significantly reduce the progression of the lung disease in cystic fibrosis<sup>7</sup>.
552 It would be interesting to investigate if better health outcomes could be reached using
553 a calcium formulation.



555

Figure 8. The effect of calcium over the permeability of naproxen, ketoprofen and indomethacin in the
presence of cystic fibrosis (CF) sputum. (A) The permeability of the three drugs measured on the CF sputum
PAMPA system and compared with PAMPA (CTRL). (B) The increase of permeability through the CF sputum
PAMPA after the formation of calcium-drug complexes. Two way ANOVA was used to compute statistical
analysis.

#### Conclusions

562 563

561

Here we used an *in vitro* pathological cystic fibrosis mucus model to explore how it can impact over permeability of a dataset of 45 compounds. Overall, our data suggest that the activity of mucus is complex to predict. Determining the specific effects limiting the permeability of drugs through mucus was out of the scope of this work. Yet, it was found that the mucus was not only a physical barrier for the permeability of drugs but also behaved as a dynamic filter as well. The permeability of most of the compounds was reduced, whilst others have not been affected by the barriers of mucus. A poor

571	correlation of the effect of mucus on permeability was found for all of the selected
572	molecular descriptors. These findings represent an additional evidence of the further
573	need for reliable in vitro mucus models to be used for drug screening, especially in
574	mucus related disorders.
575	We also ascertained that calcium, which is one of the components of our mucus model,
576	enhanced the permeability of a small group of drugs. This was most likely the result of
577	the complexation with the drug. The observed increased-permeability effect induced
578	by calcium was also achieved also through cystic fibrosis sputum, further highlighting
579	the potential to use drugs as calcium salts to pursue higher absorption rates in vivo.
580	Additionally, calcium-based formulations could offer new potentialities also for the
581	repositioning of the current therapies.
582	
583	Declaration of competing interests
584	
585	The authors declare that they have no known competing financial interests or personal
586	relationships that could have appeared to influence the work reported in this paper.
587	
588	Acknowledgements
589	
590	The authors acknowledge the financial support from the University of Torino (Ricerca
591	Locale ex-60%, Bando 2020).
592	
593	Abbreviations
594	
595	CF: cystic fibrosis
596	COPD: chronic obstructive pulmonary disease
597	PAMPA: parallel artificial membrane permeability assay.
598	PBS: phosphate buffer saline
599	HPLC-MS: high-pressure liquid chromatography – mass spectrometry
600	DMSO: dimethyl sulfoxide
601	P <sub>app</sub> : apparent permeability
602	GDL: D-(+)-gluconic acid δ-lactone
603	MRM: multiple reaction monitoring
604	PCA: principal component analysis
605	Ro5: Lipinski rule of five
606	NSAID: non-steroidal anti-inflammatory drug

607				
608	References			
609				
610	(1)	Murgia, X.; Loretz, B.; Hartwig, O.; Hittinger, M.; Lehr, C. The Role of Mucus on		
611		Drug Transport and Its Potential to Affect Therapeutic Outcomes. Adv. Drug		
612		<i>Deliv. Rev.</i> <b>2018</b> , <i>124</i> , 82–97. https://doi.org/10.1016/j.addr.2017.10.009.		
613	(2)	Cone, R. A. Barrier Properties of Mucus. Adv. Drug Deliv. Rev. 2009, 61 (2), 75-		
614		85. https://doi.org/10.1016/j.addr.2008.09.008.		
615	(3)	Fahy, J. V.; Dickey, B. F. Airway Mucus Function and Dysfunction. N. Engl. J.		
616		<i>Med.</i> <b>2010</b> , <i>363</i> (23), 2233–2247. https://doi.org/10.1056/nejmra0910061.		
617	(4)	Mitri, C.; Xu, Z.; Bardin, P.; Corvol, H.; Touqui, L.; Tabary, O. Novel Anti-		
618		Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of		
619		Molecular Targets and Design of Innovative Therapies. Front. Pharmacol.		
620		<b>2020</b> , <i>11</i> (July), 1–25. https://doi.org/10.3389/fphar.2020.01096.		
621	(5)	Meldrum, O. W.; Chotirmall, S. H. Mucus, Microbiomes and Pulmonary Disease.		
622		Biomedicines <b>2021</b> , 9 (6), 675.		
623		https://doi.org/10.3390/biomedicines9060675.		
624	(6)	Murray, M. P.; Pentland, J. L.; Turnbull, K.; MacQuarrie, S.; Hill, A. T. Sputum		
625		Colour: A Useful Clinical Tool in Non-Cystic Fibrosis Bronchiectasis. Eur.		
626		Respir. J. <b>2008</b> , 34 (2), 361–364.		
627		https://doi.org/10.1183/09031936.00163208.		
628	(7)	Konstan, M. W.; Byard, P. J.; Hoppel, C. L.; Davis, P. B. Effect of High-Dose		
629		Ibuprofen in Patients with Cystic Fibrosis. N. Engl. J. Med. 1995, 332 (13), 848-		
630		854. https://doi.org/10.1056/nejm199503303321303.		
631	(8)	Suk, J. S.; Lai, S. K.; Wang, Y. Y.; Ensign, L. M.; Zeitlin, P. L.; Boyle, M. P.; Hanes, J.		
632		The Penetration of Fresh Undiluted Sputum Expectorated by Cystic Fibrosis		
633		Patients by Non-Adhesive Polymer Nanoparticles. <i>Biomaterials</i> <b>2009</b> , <i>30</i> (13),		
634		2591–2597. https://doi.org/10.1016/j.biomaterials.2008.12.076.		
635	(9)	Yu, T.; Chisholm, J.; Choi, W. J.; Anonuevo, A.; Pulicare, S.; Zhong, W.; Chen, M.;		
636		Fridley, C.; Lai, S. K.; Ensign, L. M.; Suk, J. S.; Hanes, J. Mucus-Penetrating		
637		Nanosuspensions for Enhanced Delivery of Poorly Soluble Drugs to Mucosal		
638		Surfaces. <i>Adv. Healthc. Mater.</i> <b>2016</b> , <i>5</i> (21), 2745–2750.		
639		https://doi.org/10.1002/adhm.201600599.		
640	(10)	Boegh, M.; Nielsen, H. M. Mucus as a Barrier to Drug Delivery - Understanding		
641		and Mimicking the Barrier Properties. Basic Clin. Pharmacol. Toxicol. 2015,		
642		116 (3), 179–186. https://doi.org/10.1111/bcpt.12342.		

644Permeation Assay in the Description Of. J. Med. Chem. 1998, 41 (7), 106451010.646(12)647Artursson, P.; Palm, K.; Luthman, K. Caco-2 Monolayers in Experiment647Theoretical Predictions of Drug Transport. Adv. Drug Deliv. Rev. 2012	tal and
646 (12) Artursson, P.; Palm, K.; Luthman, K. Caco-2 Monolayers in Experimen	
647 Theoretical Predictions of Drug Transport. <i>Adv. Drug Deliv. Rev.</i> 2012	64
	, 07
648 (SUPPL.), 280–289. https://doi.org/10.1016/j.addr.2012.09.005.	
649 (13) Di, L.; Whitney-Pickett, C.; Umland, J. P.; Zhang, H.; Zhang, X.; Gebhard	, D. F.;
650 Lai, Y.; Federico III, J. J.; Davidson, R. E.; Smith, R.; Reyner, E. L.; Lee, C	.; Feng, B.;
651 Rotter, C.; Varma, M. V; Kempshall, S.; Fenner, K.; El-kattan, A. F.; Listo	on, T. E.;
652 Troutman, M. D. Development of a New Permeability Assay Using Low	v-Efflux
653 MDCKII Cells. J. Pharm. Sci. 2011, 100 (11), 4974–4985.	
654 https://doi.org/10.1002/jps.22674.	
655 (14) Sarmento, B. Concepts and Models for Drug Permeability Studies - Cell	and
656 Tissue Based In Vitro Culture Models, 1st Editio.; Woodhead Publishin,	g, 2015.
657 (15) Lock, J. Y.; Carlson, T. L.; Carrier, R. L. Mucus Models to Evaluate the D	oiffusion
658 of Drugs and Particles. <i>Adv. Drug Deliv. Rev.</i> <b>2018</b> , <i>124</i> , 34–49.	
659 https://doi.org/10.1016/j.addr.2017.11.001.	
660 (16) Butnarasu, C.; Barbero, N.; Pacheco, D.; Petrini, P.; Visentin, S. Mucin H	Binding to
661Therapeutic Molecules: The Case of Antimicrobial Agents Used in Cys	tic
<b>662</b> Fibrosis. <i>Int. J. Pharm.</i> <b>2019</b> , <i>564</i> (January), 136–144.	
663 https://doi.org/10.1016/j.ijpharm.2019.04.032.	
664 (17) Norris, D. A.; Sinko, P. J. Effect of Size, Surface Charge, and Hydrophol	oicity on
the Translocation of Polystyrene Microspheres through Gastrointesti	nal
666 Mucin. J. Appl. Polym. Sci. <b>1997</b> , 63 (11), 1481–1492.	
667 https://doi.org/10.1002/(SICI)1097-4628(19970314)63:11<1481::.	AID-
<b>668</b> APP10>3.0.C0;2-5.	
669 (18) Boegh, M.; Baldursdóttir, S. G.; Müllertz, A.; Nielsen, H. M. Property Pr	ofiling of
670 Biosimilar Mucus in a Novel Mucus-Containing in Vitro Model for Ass	essment
671 of Intestinal Drug Absorption. <i>Eur. J. Pharm. Biopharm.</i> <b>2014</b> , <i>87</i> (2), 2	227–235.
672 https://doi.org/10.1016/j.ejpb.2014.01.001.	
673 (19) Onnainty, R.; Usseglio, N.; Bonafé Allende, J. C.; Granero, G. Exploring	a New
674 Free-Standing Polyelectrolyte (PEM) Thin Film as a Predictive Tool for	or Drug-
675 Mucin Interactions: Insights on Drug Transport through Mucosal Sur	faces. <i>Int.</i>
676 <i>J. Pharm.</i> 2021, <i>604</i> (March), 120764.	
677 https://doi.org/10.1016/j.ijpharm.2021.120764.	
678 (20) Grainger, C. I.; Greenwell, L. L.; Lockley, D. J.; Martin, G. P.; Forbes, B. C	Culture of

679		Calu-3 Cells at the Air Interface Provides a Representative Model of the Airway
680		Epithelial Barrier. <i>Pharm. Res.</i> <b>2006</b> , <i>23</i> (7), 1482–1490.
681		https://doi.org/10.1007/s11095-006-0255-0.
682	(21)	Falavigna, M.; Klitgaard, M.; Brase, C.; Ternullo, S.; Škalko-Basnet, N.; Flaten, G.
683	(21)	E. Mucus-PVPA (Mucus Phospholipid Vesicle-Based Permeation Assay): An
684		Artificial Permeability Tool for Drug Screening and Formulation Development.
685		Int. J. Pharm. <b>2018</b> , 537 (1–2), 213–222.
686		
	(22)	https://doi.org/10.1016/j.ijpharm.2017.12.038.
687 688	(22)	Pacheco, D. P.; Butnarasu, C. S.; Briatico Vangosa, F.; Pastorino, L.; Visai, L.;
688		Visentin, S.; Petrini, P. Disassembling the Complexity of Mucus Barriers to
689		Develop a Fast Screening Tool for Early Drug Discovery. J. Mater. Chem. B
690		<b>2019</b> , 7 (32), 4940–4952. https://doi.org/10.1039/C9TB00957D.
691	(23)	Hentzer, M.; Teitzel, G. M.; Balzer, G. J.; Heydorn, A.; Molin, S.; Givskov, M.;
692		Parsek, M. R. Alginate Overproduction Affects Pseudomonas Aeruginosa
693		Biofilm Structure and Function. <i>J. Bacteriol.</i> <b>2001</b> , <i>183</i> (18), 5395–5401.
694		https://doi.org/10.1128/JB.183.18.5395-5401.2001.
695	(24)	Leid, J. G.; Willson, C. J.; Shirtliff, M. E.; Hassett, D. J.; Parsek, M. R.; Jeffers, A. K.
696		The Exopolysaccharide Alginate Protects Pseudomonas Aeruginosa Biofilm
697		Bacteria from IFN-γ-Mediated Macrophage Killing . <i>J. Immunol.</i> <b>2005</b> , <i>175</i> (11),
698		7512–7518. https://doi.org/10.4049/jimmunol.175.11.7512.
699	(25)	Bidmon, K.; Lieleg, O.; Berensmeier, S. An Optimized Purification Process for
700		Porcine Gastric Mucin with Preservation of Its Native Functional Properties.
701		<i>RSC Adv.</i> <b>2016</b> , <i>6</i> , 44932–44943. https://doi.org/10.1039/C6RA07424C.
702	(26)	Wishart, D. S.; Knox, C.; Guo, A. C.; Shrivastava, S.; Hassanali, M.; Stothard, P.;
703		Chang, Z.; Woolsey, J. DrugBank: A Comprehensive Resource for in Silico Drug
704		Discovery and Exploration. Nucleic Acids Res. 2006, 34 (Database issue), 668–
705		672. https://doi.org/10.1093/nar/gkj067.
706	(27)	Kim, S.; Chen, J.; Cheng, T.; Gindulyte, A.; He, J.; He, S.; Li, Q.; Shoemaker, B. A.;
707		Thiessen, P. A.; Yu, B.; Zaslavsky, L.; Zhang, J.; Bolton, E. E. PubChem in 2021:
708		New Data Content and Improved Web Interfaces. Nucleic Acids Res. 2021, 49
709		(D1), D1388–D1395. https://doi.org/10.1093/nar/gkaa971.
710	(28)	Sharifian Gh., M. Recent Experimental Developments in Studying Passive
711		Membrane Transport of Drug Molecules. <i>Mol. Pharm.</i> <b>2021</b> .
712		https://doi.org/10.1021/acs.molpharmaceut.1c00009.
713	(29)	Oriano, M.; Terranova, L.; Sotgiu, G.; Saderi, L.; Bellofiore, A.; Retucci, M.;
714		Marotta, C.; Gramegna, A.; Miglietta, D.; Carnini, C.; Marchisio, P.; Chalmers, J.
-		, , , , , , , , , , , , , , , , , , ,

715		D.; Aliberti, S.; Blasi, F. Evaluation of Active Neutrophil Elastase in Sputum of
716		Bronchiectasis and Cystic Fibrosis Patients: A Comparison among Different
717		Techniques. Pulm. Pharmacol. Ther. 2019, 59 (October), 1–6.
718		https://doi.org/10.1016/j.pupt.2019.101856.
719	(30)	Chen, X.; Murawski, A.; Patel, K.; Crespi, C. L.; Balimane, P. V. A Novel Design of
720		Artificial Membrane for Improving the PAMPA Model. Pharm. Res. 2008, 25
721		(7), 1511–1520. https://doi.org/10.1007/s11095-007-9517-8.
722	(31)	Teixeira, L. de S.; Chagas, T. V.; Alonso, A.; Gonzalez-alvarez, I.; Bermejo, M.;
723		Polli, J.; Rezende, K. R. Biomimetic Artificial Membrane Permeability Assay
724		over Franz Cell Apparatus Using Bcs Model Drugs. <i>Pharmaceutics</i> <b>2020</b> , <i>12</i>
725		(10), 1–16. https://doi.org/10.3390/pharmaceutics12100988.
726	(32)	Sugano, K.; Takata, N.; Machida, M.; Saitoh, K.; Terada, K. Prediction of Passive
727		Intestinal Absorption Using Bio-Mimetic Artificial Membrane Permeation
728		Assay and the Paracellular Pathway Model. Int. J. Pharm. 2002, 241 (2), 241–
729		251. https://doi.org/10.1016/S0378-5173(02)00240-5.
730	(33)	Artursson, P.; Bergström, C. A. S. Intestinal Absorption: The Role of Polar
731		Surface Area. Drug Bioavailability. May 27, 2003, pp 339–357.
732		https://doi.org/https://doi.org/10.1002/3527601473.ch15.
733	(34)	Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High Throughput
734		Artificial Membrane Permeability Assay for Blood-Brain Barrier. Eur. J. Med.
735		Chem. 2003, 38 (3), 223–232. https://doi.org/10.1016/S0223-
736		5234(03)00012-6.
737	(35)	Köllmer, M.; Mossahebi, P.; Sacharow, E.; Gorissen, S.; Gräfe, N.; Evers, D. H.;
738		Herbig, M. E. Investigation of the Compatibility of the Skin PAMPA Model with
739		Topical Formulation and Acceptor Media Additives Using Different Assay
740		Setups. AAPS PharmSciTech <b>2019</b> , 20 (2), 1–10.
741		https://doi.org/10.1208/s12249-019-1305-3.
742	(36)	Matsson, P.; Kihlberg, J. How Big Is Too Big for Cell Permeability? J. Med. Chem.
743		<b>2017</b> , <i>60</i> (5), 1662–1664. https://doi.org/10.1021/acs.jmedchem.7b00237.
744	(37)	Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Structure-Brain Exposure
745		Relationships. J. Med. Chem. <b>2006</b> , 49 (17), 12–14.
746		https://doi.org/10.1021/jm060379l.
747	(38)	Shityakov, S.; Neuhaus, W.; Dandekar, T.; Förster, C. Analysing Molecular Polar
748		Surface Descriptors to Predict Blood-Brain Barrier Permeation. Int. J. Comput.
749		Biol. Drug Des. <b>2013</b> , 6 (1-2), 146–156.
750		https://doi.org/10.1504/IJCBDD.2013.052195.

751	(39)	Tang, B.; Wang, J.; Wang, Q.; Xiao, Y.; Huang, Y.; Liao, X.; Li, H. Calcium(II)–
752		Naproxen Complex: Synthesis, Characterization, and Interaction with Human
753		Serum Albumin. Spectrosc. Lett. 2016, 49 (6), 404–412.
754		https://doi.org/10.1080/00387010.2016.1174137.
755	(40)	Atassi, F.; Mao, C.; Masadeh, A. S.; Byrn, S. R. Solid-State Characterization of
756		Amorphous and Mesomorphous Calcium Ketoprofen. J. Pharm. Sci. 2010, 99
757		(9), 3684–3697. https://doi.org/10.1002/jps.21925.
758	(41)	Ogiso, T.; Ito, Y.; Iwaki, M.; Atago, H. Absorption of Indomethacin and Its
759		Calcium Salt through Rat Skin: Effect of Penetration Enhancers and
760		Relationship between in Vivo and in Vitro Penetration. J. Pharmacobiodyn.
761		<b>1986</b> , <i>9</i> , 517–525.
762	(42)	Mandel, I. D.; Eriv, A.; Kutscher, A.; Denning, C.; Thompson, R. H.; Kessler, W.;
763		Zegarelli, E. Calcium and Phosphorus Levels in Submaxillary Saliva. Clin.
764		Pediatr. (Phila). <b>1969</b> , 8 (3), 161–164.
765		https://doi.org/10.1177/000992286900800308.
766		